Pro-inflammatory immune profile mediated by TNF and IFN-γ and regulated by IL-10 is associated to IgG anti-SARS-CoV-2 in asymptomatic blood donors

Chaves, Daniel Gonçalves; Oliveira, Leonardo Camilo de; Malta, Maria Clara Fernandes da Silva; Oliveira, Isabelle Rocha de; Barbosa-Stancioli, Edel Figueiredo; Teixeira, Mauro Martins; Martins, Marina Lobato

doi:10.1016/j.cyto.2022.155874

Cited by 3 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CXCL9 and CXCL10 are known to play a crucial role in the human antiviral response, and their concentrations have been previously related to COVID-19 infection and its severity 10 . We previously found a significant strong or moderate inverse correlation between the neutralizing capacity of anti-SARS-CoV-2 IgG antibodies and the levels of CCL5, CXCL9, and CXCL10 11 , suggesting that humoral responsiveness influences the chemokine production network.…”

Section: Univariate Analysis (Tablementioning

confidence: 95%

A potent inflammatory response is triggered in asymptomatic blood donors with recent SARS-CoV-2 infection

Martins

Silva-Malta

Araújo

et al. 2022

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Authors' contribution: MLM, MCFS-M and DGC performed study conception and design. MLB and FAG enrolled the patients and collected their samples. MAR and ALA designed patients' clinical data and ALA collected them. MLM, MCFS-M, IRO, LSMFB, HMM and DGC performed laboratory tests. MLM, MCFS-M and DGC performed data analysis and prepared the manuscript, and EFB-S performed its critical evaluation. All authors read and approved the final manuscript.

show abstract

Section: Univariate Analysis (Tablementioning

confidence: 95%

A potent inflammatory response is triggered in asymptomatic blood donors with recent SARS-CoV-2 infection

Martins

Silva-Malta

Araújo

et al. 2022

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

show abstract

“…We performed plaque reduction neutralization tests (PRNT) on serum samples from all captured coatis to detect SARS-CoV-2 neutralizing antibodies ( 8 ). We serially diluted serum samples to obtain 1:20, 1:40, and 1:80 dilutions and measured 50% and 90% neutralizing activity against SARS-CoV-2.…”

mentioning

confidence: 99%

SARS-CoV-2 Spillback to Wild Coatis in Sylvatic–Urban Hotspot, Brazil

Stoffella-Dutra¹,

Campos²,

Silva³

et al. 2023

Emerg. Infect. Dis.

Self Cite

View full text Add to dashboard Cite

show abstract

Seroprevalence of SARS-CoV-2 antibodies among healthy blood donors: a systematic review and meta-analysis

Ukwishaka,

Fotabong,

Aseneh

et al. 2023

Preprint

View full text Add to dashboard Cite

Introduction: The development of a potent immune response and antibodies against SARS-CoV-2 is important for attaining herd immunity. This serological response could be due to past infection or vaccines. Healthy blood donors could represent and provide information on the immune status of the general population. Hence, we estimated the global and regional prevalence of SARS-CoV-2 antibodies among healthy asymptomatic blood donors. Methods: We systematically searched PubMed, Scopus, and ProQuest for eligible articles published between December 1, 2019, and January 12, 2023, without language restrictions. After critical appraisal and quality assessment, a qualitative synthesis of the identified pertinent articles was performed. The random-effect model was used to estimate the pooled prevalence of SARS-CoV-2 antibodies. Funnel plots and Egger’s test were used to assess publication bias. Sensitivity analysis was performed, and heterogeneity was quantified using I2 statistics. Results: A total of 70 peer-reviewed articles were selected and included 2,453,937 blood donors. The global estimated pooled prevalence of SARS-CoV-2 antibodies among healthy blood donors was 10.9% (95% CI: 5.0 – 18.8%, n=68). A high seroprevalence of SARS-CoV-2 was observed in Asia (20.4%, 95% CI: 10.1 – 33.1%, n=24), followed by Africa (16.1%, 95% CI: 6.8 – 28.3%, n=7). The seroprevalence of SARS-CoV-2 in studies conducted before the introduction of the vaccine was 6.5% (95% CI: 4.9 – 8.3%, n=50), while that of studies conducted after the vaccine was 27.6% (95% CI: 12.4 – 46.2% n=18). High seroprevalence was observed in studies that measured antibodies against the S protein of the virus (16.2%, 95% CI: 11.4 – 21.8%, n=27), while it was 12.5% (95% CI: 5.3 – 22.1%, n=16) in those that measured antibodies against the N protein. A high seroprevalence of SARS-CoV-2 was observed in studies that only measured IgG antibodies (17.2%, 95% CI: 10.5 – 25.1%, n=33) and in studies that measured total antibodies to SARS-CoV-2 (6.2%, 95% CI: 0.7 – 16.5%, n=33). Conclusion: In view of all evidence, there is variation in the prevalence of SARS-CoV-2 antibodies among healthy blood donors globally. Noticeably, there is a regional difference that could depict differences in transmission and vaccination rates. Based on the results of our analysis, we recommend evidence-based booster vaccination strategies informed by seroprevalence trends and waning immunity and reinforcing seroprevalence surveillance for outbreak management. It is advisable to mitigate socioeconomic disparities through inclusive health policies coupled with adaptable public health measures given local seroprevalence rates. These will contribute to informed policy decisions to build community resilience during the post-PHEIC phase of the COVID-19 pandemic.

show abstract

Pro-inflammatory immune profile mediated by TNF and IFN-γ and regulated by IL-10 is associated to IgG anti-SARS-CoV-2 in asymptomatic blood donors

Cited by 3 publications

References 27 publications

A potent inflammatory response is triggered in asymptomatic blood donors with recent SARS-CoV-2 infection

A potent inflammatory response is triggered in asymptomatic blood donors with recent SARS-CoV-2 infection

SARS-CoV-2 Spillback to Wild Coatis in Sylvatic–Urban Hotspot, Brazil

Seroprevalence of SARS-CoV-2 antibodies among healthy blood donors: a systematic review and meta-analysis

Contact Info

Product

Resources

About